PI3Kinase based degradation of NRF2 signaling in chemo-radiation resistant HNSCC

Head and neck squamous cell carcinoma is a formidable type of cancer that affects the mouth, throat, and voice box. For many patients, the standard treatment involves a grueling combination of chemotherapy and radiation therapy. Yet, despite these aggressive efforts, the disease often returns, resistant to further treatment. A major reason for this stubborn resistance lies within the cancer cells themselves. These cells have developed a sophisticated internal defense system centered on a protein called NRF2. Under normal circumstances, the body uses a specific mechanism to break down NRF2, keeping its levels in check. However, in many resistant tumors, this breakdown system is broken or bypassed, allowing NRF2 to accumulate. This excess protein acts like a shield, neutralizing the toxic free radicals generated by radiation and chemotherapy, effectively disarming the very weapons doctors use to kill the cancer.

Scientists have long known that NRF2 is a problem, but they have struggled to find a way to turn it off, especially in tumors where the usual breakdown switch is broken. A new study from researchers at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center offers a fresh perspective. Instead of trying to fix the broken switch, the team explored a different pathway entirely. They investigated a drug called gedatolisib, which is already being tested in other cancers, to see if it could force the cancer cells to destroy their own NRF2 shield using a completely different set of tools. The researchers found that the drug successfully reactivated a backup degradation system, stripping the cancer cells of their protection and making them vulnerable to treatment once again.

The team began by testing this drug on a wide variety of head and neck cancer cells, including some that had become resistant to cisplatin, a common chemotherapy agent. They observed that when the cells were exposed to gedatolisib, the levels of the protective NRF2 protein dropped significantly. This was a surprising discovery because the drug did not stop the cells from making the instructions for NRF2. In fact, the cells actually tried to make more of the protein's genetic code in response to the drug. The key was that the drug accelerated the destruction of the protein itself faster than the cells could build new ones. It was as if the factory was running at full speed, but the delivery trucks were removing the finished product so quickly that the warehouse remained empty.

To understand how this happened, the researchers looked deeper into the cellular machinery. They discovered that the drug works by turning off a signaling pathway that usually keeps a specific enzyme, known as GSK3, inactive. Normally, this enzyme is held in check, but when the drug blocks the signal that keeps it sleeping, the enzyme wakes up. Once active, this enzyme tags the NRF2 protein for immediate disposal. The cell then sends these tagged proteins to its internal recycling center, the proteasome, where they are shredded. This process happens even in cancer cells where the primary breakdown system is broken, proving that the drug uses a completely different route to achieve the same result. The researchers confirmed this by showing that if they blocked this backup enzyme or the recycling center, the drug stopped working, and the NRF2 levels remained high.

The study also examined what happens to the cancer cells after they lose their NRF2 shield. Using advanced imaging techniques that allow scientists to watch living cells in real time without harming them, the team saw that the treated cells did not simply fade away. Instead, they underwent a chaotic form of cell death known as necrosis. The cells swelled, their internal power plants, the mitochondria, began to clump together, and the cells eventually burst. This was a distinct pattern from the more orderly cell death usually seen with radiation alone, suggesting the drug causes a metabolic collapse that overwhelms the cell's defenses.

The researchers then moved from the laboratory to living animals to see if these findings held true in a more complex environment. They used a special model where cancer cells were grown directly in the tongues of mice, mimicking the actual location and environment of human head and neck tumors. In these animals, the drug alone was powerful enough to shrink tumors significantly, even in mice whose cancer cells had lost the primary NRF2 breakdown mechanism. When the drug was combined with radiation therapy, the results were even more striking. The combination did not just add the effects of the two treatments together; it multiplied them. In one experiment, the combination of the drug and radiation reduced tumor volume by nearly eighty percent compared to the control group, and in another, the tumors were nearly forty times smaller than those in untreated mice.

This approach is particularly promising because it addresses a specific weakness in the most difficult-to-treat cancers. The study showed that the drug worked effectively in cells that had become resistant to cisplatin, a situation where the chemotherapy drug alone offered no benefit. By removing the NRF2 shield, the drug restored the cancer cells' sensitivity to radiation, allowing the radiation to do its job. The researchers noted that while the drug worked well in these models, the response varied depending on the specific genetic makeup of the tumor, suggesting that not every patient would respond in the exact same way. However, the consistent ability to degrade NRF2 through this alternative pathway provides a strong foundation for future clinical trials.

The implications of this work extend beyond just finding a new way to kill cancer cells. It reveals a complex balance within the cell where the production of a protein and its destruction are constantly competing. The drug tipped this balance decisively toward destruction, even when the cell tried to compensate by making more of the protein. This finding challenges the idea that simply blocking the production of a protein is the only way to lower its levels. Instead, it highlights the potential of targeting the machinery that removes proteins, offering a new strategy for cancers that have learned to ignore traditional treatments.

While the study was conducted in cells and mice, the results point toward a tangible path forward for human patients. The drug used, gedatolisib, is already in advanced stages of testing for other types of cancer, which means it could potentially be moved into trials for head and neck cancer more quickly than a completely new drug. The researchers emphasize that their work provides a clear mechanism for how this drug works and suggests that it could be a valuable addition to standard radiation therapy. By stripping the cancer of its antioxidant shield, this approach could turn resistant tumors back into treatable ones, offering new hope for patients who have run out of options. The study does not claim to have solved the problem of head and neck cancer, but it has identified a specific, actionable vulnerability that can be exploited to improve the effectiveness of existing treatments.